Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
ConditionSmall Cell Lung Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorYunpeng Liu
About this trial
To evaluate the efficacy and safety of maintenance therapy with Adebrelimab plus Apatinib for extensive stage small cell lung cancer after first-line induction of Adebrelimab plus chemotherapy.
Eligibility criteria
Qualifiers
Participants voluntarily enrolled in this study and signed an informed consent form, were compliant and co-operated with follow-up visits;
Age 18 years and above, male and female;
Diagnosis of extensive stage small cell lung cancer (ES-SCLC) confirmed by histology or pathology (according to the American Veterans Lung Cancer Association, VALG stage);
ECOG physical condition score is 0-2;
Disqualifiers
Patients with meningeal metastases;
Prior treatment with any T-cell co-stimulation or immune checkpoint therapy, including, but not limited to, cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors, CD137 agonists, or other agents that target T cells;
Prior treatment with apatinib;
Factors affecting oral administration of medications such as inability to swallow, post gastrointestinal resection, chronic diarrhoea, intestinal obstruction;
Trial design
Treatments tested in this trial
- Adebrelimab Injection
- Apatinib Mesylate Tablets
- Carboplatin
- Cisplatin
- Etoposide
Treatment groups
38 Participants
are divided into 1 treatment groupSponsors and collaborators
Yunpeng Liu
Lead sponsor
China Medical University, China
Sponsor institution
Jiangsu HengRui Medicine Co., Ltd.
Collaborator
Source ClinicalTrials.gov